Beyond Air earnings date
Beyond Air (48L) Q2 2027 Earnings Report
DE:48L Q2 2027 EPS Results
- Actual EPS
- -EUR 3.41
- Consensus EPS
- -EUR 3.00
- Beat/Miss
- Missed by -EUR 0.41
- One Year Ago EPS
- -EUR 22.68
DE:48L Q2 2027 Revenue Results
- Actual Revenue
- EUR 2.11M
- Expected Revenue
- EUR 1.96M
- Beat/Miss
- Beat by +EUR 146.05K
- YoY Revenue Growth
- +27.83%
Earnings Announcement Details
- Quarter
- Q2 2027
- Date
- 11/11/2026
- Time
- After Close
- Conference Call
- Wednesday, November 11, 2026
Beyond Air's next earnings date is estimated for February 11, 2027, based on past reporting schedules.
Q2 2027 Earnings Call Audio
Q2 2027 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2027 Earnings Call Summary
The call was predominantly positive, supported by record revenue, 28% year-over-year growth, improved gross margin, a rapidly expanding commercial pipeline, increasing win rates, strong customer acceptance, and reaffirmed 2026 and 2027 revenue guidance. The company also reported progress toward FDA approval of its second-generation system and strategic actions for non-core programs. Offsetting factors included the continued $7.8 million quarterly net loss, higher other expense, limited cash including restricted cash, pending FDA approval, and the decision not to fund further LungFit GO development in 2027.
Beyond Air reaffirmed revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation system, and $16 million to $18 million for calendar year 2027, which includes anticipated revenue from the second-generation system pending FDA approval; management said the 2027 guidance includes Gen 2 only in the second, third, and fourth quarter, with no Gen 2 revenue in the first quarter, and said it is not expecting to push anything out. The company expects to complete its audit readiness process in mid-December; the actual audit is expected to be only like a day and a half long, with a response within a few weeks.
- Record Quarterly Revenue GrowthRevenue reached a record $2.3 million in the September 2026 quarter, up approximately 28% year-over-year from $1.8 million and 31% from the June 2026 quarter.
- Improved Gross Margin and Gross ProfitGross margin improved to approximately 8% from negative 16% in the prior-year quarter. Gross profit was $200,000 compared with a gross loss of $300,000 in the same period last year.
- Expanding Commercial PipelineThe U.S. commercial pipeline has grown close to fourfold from the first quarter of 2026 and has more than doubled after the company cleaned up legacy deals and added greater rigor to its pipeline definition.
- Growing Customer Wins and RenewalsThe company reported a strong pace of new account wins and renewals, with dozens and dozens of hospitals using the first-generation LungFit PH system and a couple hundred units deployed.
- Technology Acceptance and Higher Win RatesManagement said LungFit PH has been well received for its ease of use and innovative delivery of inhaled nitric oxide. Referenceable customers and positive feedback from hospital systems are helping increase the company's win rate.
- International and VA Business ContributionInternational partnerships cover more than 40 countries, and international sales during the quarter were among the company's highest to date. International direct sales and recent wins in the VA system are contributing directly to revenue.
- Second-Generation LungFit PH Nearing FDA Review CompletionThe PMA supplement for the second-generation LungFit PH remains under FDA review, with audit readiness expected to be completed in mid-December. Management stated that the remaining process consists of FDA inspections and final approval, with the actual audit expected to last approximately a day and a half.
- Enhanced Second-Generation Product FeaturesPending FDA approval, the second-generation system is smaller, lighter, easier to operate, has longer service intervals, and offers expanded operational flexibility. The PMA supplement seeks labeling that would permit use during air and ground patient transport.
- Transport Capability Could Expand Hospital UseManagement said transport capability would enable Beyond Air to serve as a single-source nitric oxide provider across routine care and patient transport, consistent with the current standard across most U.S. hospital systems.
- LungFit GO Receives Breakthrough Device DesignationLungFit GO received FDA breakthrough device designation during the quarter for treatment of nontuberculous mycobacterial pulmonary disease, or NTM-PD.
- Revenue Guidance ReaffirmedThe company reaffirmed calendar-year 2026 revenue guidance of $8 million, excluding revenue from the second-generation system, and calendar-year 2027 revenue guidance of $16 million to $18 million, including anticipated second-generation revenue in the second, third, and fourth quarters pending FDA approval.
- Operating Expense ReductionsResearch and development expenses declined to $1.6 million from $2.5 million, primarily because most second-generation LungFit PH development was complete. Selling, general, and administrative expenses declined to $4.6 million from $4.9 million, primarily due to lower stock-based compensation costs.
- Strategic Actions for Non-Core ProgramsBeyond Air entered into a definitive agreement for UNIVO Pharmaceuticals Industries to acquire its controlling interest in NeuroNOS Israel, with the transaction intended to provide NeuroNOS with dedicated resources, funding, and strategic focus. Beyond Air is also evaluating development partnerships and other strategic arrangements for Beyond Cancer while maintaining focus on LungFit PH commercialization.
- Pipeline Conversion Already BeginningManagement stated that the expanding pipeline is already beginning to translate into revenue, that the win rate is increasing, and that fewer competitors in the field are expected to support a higher win rate.
- Average Deal Size and Future Larger DealsThe current average deal size is approximately $250,000, with deals ranging from $30,000 to more than $1 million. Management expects the next-generation product to compete for much larger deals and increase the overall average deal size.
DE:48L Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 11, 2027 | 2027 (Q3) | -2.05- | -15.42 | ― | ― |
| Nov 11, 2026 | 2027 (Q2) | -3.00-3.41 | -22.68 | 84.96% (+19.27) | |
| Aug 13, 2026 | 2027 (Q1) | -9.80-9.98 | -27.76 | 64.05% (+17.78) | |
| Jun 26, 2026 | 2026 (Q4) | -10.28-13.97 | -32.66 | 57.22% (+18.69) | |
| Feb 13, 2026 | 2026 (Q3) | -13.62-15.42 | -54.43 | 71.67% (+39.01) | |
| Nov 10, 2025 | 2026 (Q2) | -14.03-22.68 | -101.6 | 77.68% (+78.92) | |
| Aug 12, 2025 | 2026 (Q1) | -22.28-27.76 | -97.97 | 71.67% (+70.21) | |
| Jun 17, 2025 | 2025 (Q4) | -44.27-32.66 | -130.63 | 75.00% (+97.97) | |
| Feb 10, 2025 | 2025 (Q3) | -57.84-54.43 | -181.43 | 70.00% (+127.00) | |
| Nov 11, 2024 | 2025 (Q2) | -103.05-101.60 | -185.06 | 45.10% (+83.46) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
